Aptar Pharma Twister Chosen for Asthma Therapy

Aptar Pharma has partnered with Shanghai Sine Promod Pharmaceutical to develop and launch its new Budesonide Dry Powder Inhaler (DPI), which uses Aptar Pharma’s novel, user-friendly and cost-effective Twister DPI.

The first drug product marketed with Twister Budesonide DPI is designed for maintenance therapy in the treatment of asthma. Budesonide DPI is one of the first drug products manufactured locally and marketed in China. This cost-effective drug product incorporates Aptar Pharma’s Twister technology. Budesonide DPI contains an inhaled corticosteroid for the treatment of asthma in adults and children age six and over. The product is marketed in two versions, one version containing 30 capsules and the other, 60 capsules.
Each capsule consists of 200µg of budesonide blended with lactose monohydrate as the carrier.

Key benefits of Aptar Pharma’s Twister 

Twister is a new capsule-based DPI, designed and developed by a multidisciplinary technical team based at Aptar Pharma’s Centre of Excellence in Le Vaudreuil, France to specifically address unmet medical needs in fast-growing markets.

Twister has a simple and robust design with few components, making it costeffective for asthma and COPD treatments, and has been tested and validated with a number of different dry powder drug formulations.

Twister is designed to be patient-friendly and easy to use, allowing patients easy access to their medication in three simple steps: insert, twist and inhale. To help improve patient compliance with the prescribed treatment, Twister is transparent, allowing the capsule and powder to be seen in the device as they are administered. In addition to these visual cues, the patient is also guided by audible feedback during inhalation.

“Shanghai Sine Promod Pharmaceutical is one of Aptar Pharma’s key customers in China. We are particularly proud to have supported their Budesonide DPI program through the development and commercialization of Twister, manufactured locally in our Suzhou facility. This is a very important milestone for Aptar Pharma China,” stated Mrs Yan Jiang, Vice President Northeast Asia for Aptar Pharma.